Background: Urinary levels of epidermal growth factor to creatinine ratio are considered as an early predictor of interstitial kidney fibrosis but so far no data are available on their biological variation (BV) and derived parameters. The aim of this study is to determine the BV of epidermal growth factor to creatinine ratio in patients with chronic kidney disease and in healthy volunteers.

Methods: This cross-sectional study included 150 patients with chronic kidney disease (CKD) and 150 healthy volunteers (HV). In both groups, spot second-morning urine samples were collected once a week for 4 consecutive weeks. Measurements of EGF were done by ELISA and expressed as EGF/creatinine ratio. The components of BV, individuality index (II), and reference change values (RCV) were calculated.

Results: The analytical coefficient of variation (CVa) of EGF/creatinine ratio was 3.8% in patients with CKD and 3.9% in HV. The within-patient variation coefficient (CVw) was 11.2% in CKD and 12.1% in HV. The between-patient coefficient of variation (CVg) was 34% in CKD and 22% in HV. In both groups, CVa met the optimum analytical quality specifications for imprecision, since it was lower than 25% of CVw. There were no significant differences between CKD and HV in the analytical or in the within-patient variances of the EGF/creatinine ratio. The between-patient EGF/creatinine ratio variance was significantly higher in patients with CKD than in HV (F: 48.3, p: 0.000). The EGF/creatinine ratio showed an individuality index (II) of 0.3 in CKD and 0.5 in HV. The reference change value (RCV) was 29.2% in CKD and 31.6% in HV.

Conclusions: The CVa associated with the measurement techniques used in our study meets the optimal criteria of analytical imprecision. The urine EGF/creatinine ratio shows a high index of individuality both in patients with CKD and in HV, so the comparison of an isolated value with a reference interval is of little use. In the monitoring of repeated levels in the same individual or patient, the changes can only be considered significant when they are greater than 30% in relation to the previous values.

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2019.190304DOI Listing

Publication Analysis

Top Keywords

egf/creatinine ratio
24
epidermal growth
12
patients chronic
12
chronic kidney
12
kidney disease
12
patients ckd
12
ratio
9
ckd
9
ratio patients
8
disease healthy
8

Similar Publications

Background: Urinary levels of epidermal growth factor to creatinine ratio are considered as an early predictor of interstitial kidney fibrosis but so far no data are available on their biological variation (BV) and derived parameters. The aim of this study is to determine the BV of epidermal growth factor to creatinine ratio in patients with chronic kidney disease and in healthy volunteers.

Methods: This cross-sectional study included 150 patients with chronic kidney disease (CKD) and 150 healthy volunteers (HV).

View Article and Find Full Text PDF

Background: Urinary levels of EGF may be a noninvasive biomarker of the degree of interstitial fibrosis. However, all the available data are based on studies that examined the EGF/creatinine ratio in spot urine samples. The agreement between EGF/creatinine ratio and 24-hours EGF excretion has not been analyzed, neither has it been established which of these two measurements is a better predictor of the degree of interstitial fibrosis.

View Article and Find Full Text PDF

To investigate the excretion of urinary epidermal growth factor (EGF) in children with chronic renal failure (CRF), we have measured the urinary EGF/creatinine ratio (EGF/Cr) and the 24-hour urine EGF concentration in 19 children with CRF, 11 children with kidney disease and normal creatinine clearance, and 12 healthy children. Children with CRF had a significantly lower daily urine EGF concentration as well as urinary EGF/Cr. In contrast, children with kidney disease and normal renal function had normal daily urine EGF levels and urinary EGF/Cr.

View Article and Find Full Text PDF

Unlabelled: Epidermal growth factor (EGF) is synthesized in the kidneys and excreted in urine. Administration of exogenous EGF modulates the reabsorption of Na+ and the vasopressin stimulated reabsorption of water in the collecting tubules. In order to clarify whether this reflects a physiological role for urinary EGF we examined the effects of changes in the oral loads of water, Na+ and NH4+ as well as the effect of infusion of the vasopressin analogue, desmopressin (DDAVP) on the endogenous urinary EGF excretion in the rat.

View Article and Find Full Text PDF

[Urinary epidermal growth factor and serum pepsinogen I in patients with duodenal ulcers].

G E N

December 1993

Departamento de Medicina, Pediatría y Farmacología, Universidad de Carabobo.

Absolute and corrected by creatinine excretion urinary Epidermal Growth Factor (EGF) values were determined in 23 duodenal ulcer patients and compared to a control group. Basal serum pepsinogen I levels were measured in the patient group. Absolute urinary EGF values in patients were lower than in control group, such difference however, as such of EGF corrected by urinary creatinine excretion were not statistically significant (p > 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!